Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages 1763-1770

  Cersosimo, E ^a,b   Gastaldelli, A ^a,c   Cervera, A ^a   Wajcberg, E ^a   Sriwijilkamol, A ^a   Fernandez, M ^a   Zuo, P ^a   Petz, R ^c   Triplitt, C ^a,b   Musi, N ^a,b   DeFronzo, Ralph A ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b Texas Diabetes Institute   (United States)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH EMPTYING; TREATMENT DURATION;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; VENOMS;

RATTUS;

EID: 79956336447     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2146     Document Type: Article

References (33)

1. Defronzo RA 2009 Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795
2. Holst JJ, Gromada J 2004 Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287:E199-E206 (Pubitemid 38943883)
3. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723 (Pubitemid 32755966)
4. Samson SL GE, Sathyanarayana P, Bajaj M, Chan L 2009 Exendin 4 down regulates gluconeogenic gene expression and gluconeogenesis in vivo and in isolated hepatocytes in vitro. Diabetes 58:A3
5. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA 2002 Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45:1410-1415
6. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD 2008 Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization. Am J Physiol Endocrinol Metab 294:E380-E384 (Pubitemid 351231465)
7. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ 2009 One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32:762-768
8. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E 2008 Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 294:E846-E852
9. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100 (Pubitemid 40616618)
10. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L 2008 Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24:2943-2952
11. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA 2007 The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249-1255 (Pubitemid 46556394)
12. Burcelin R, Da Costa A, Drucker D, Thorens B 2001 Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50:1720-1728 (Pubitemid 33641588)
13. 2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772-1779
14. Dardevet D, Moore MC, DiCostanzo CA, Farmer B, Neal DW, Snead W, Lautz M, Cherrington AD 2005 Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol 289:G806-G814 (Pubitemid 41532573)
15. Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang X, Duttaroy A, Cherrington AD 2009 Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like peptide 1 infusion increases liver glucose uptake in the conscious dog. Diabetes 58:243-249
16. Ionut V, Zheng D, Stefanovski D, Bergman RN 2008 Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am J Physiol Endocrinol Metab 295:E269-E277
17. Blase E, Taylor K, Gao HY, Wintle M, Fineman M 2005 Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 45:570-577 (Pubitemid 40562948)
18. Ferrannini E, Simonson DC, Katz LD, Reichard G Jr, Bevilacqua S, Barrett EJ, Olsson M, DeFronzo RA 1988 The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 37:79-85 (Pubitemid 18057200)
19. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA 2007 Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133:496-506 (Pubitemid 47187337)
20. Hovorka R, Soons PA, Young MA 1996 ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50:253-264 (Pubitemid 26308809)
21. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA 2006 Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55:1430-1435 (Pubitemid 44195383)
22. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470 (Pubitemid 29418240)
23. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW 1994 Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266 (Pubitemid 24143111)
24. Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O 1996 GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232
25. Ryan AS, Egan JM, Habener JF, Elahi D 1998 Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83:2399-2404 (Pubitemid 28503037)
26. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA 2000 Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49:611-617 (Pubitemid 30183750)
27. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ 2001 Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613 (Pubitemid 32195226)
28. Basu A, Basu R, Shah P, Vella A, Johnson CM, Nair KS, Jensen MD, Schwenk WF, Rizza RA 2000 Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes 49:272-283 (Pubitemid 30071006)
29. DeFronzo RA, Ferrannini E, Hendler R, Wahren J, Felig P 1978 Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci USA 75:5173-5177 (Pubitemid 9046504)
30. Ferrannini E, Wahren J, Felig P, DeFronzo RA 1980 The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. Metabolism 29:28-35 (Pubitemid 10208102)
31. DeFronzo F, Ferrannini E, Wahren J, Felig P 1978 Lack of a gastrointestinal mediator of insulin action in maturity-onset diabetes. Lancet 2:1077-1079 (Pubitemid 9052865)
32. Triplitt C, DeFronzo, RA 2006 Exenatide: first in class incretin mimetic for the treatment of type 2 diabetes mellitus. Exp Rev Endocirnol Metab 1:329-341
33. Kjems LL, Holst JJ, Vølund A, Madsbad S 2003 The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386 (Pubitemid 36173193)